In particular, gastrointestinal and brain toxicity is more common with anti-CTLA-4 drugs, while hypothyroidism, hepatotoxicity and pneumonitis are more frequent in cases of anti-PD-1-targeted therapies (Waldman et al., 2020). This evidence concerns the gene PDCD1 and pneumonitis.